UK government bolsters antiviral supply for hantavirus
The UK has received doses of antiviral medicine favipiravir as a precaution in case hantavirus spreads in the country. The…
19 May 2026
VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain
VERTANICAL has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for VER-01, its investigational non-opioid treatment for chronic low back pain. The designation follows two randomised,…
19 May 2026
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Regeneron Pharmaceuticals has signed a $2.32bn research collaboration with Parabilis Medicines to develop therapeutic candidates leveraging the latter’s Helicon peptide platform, with an emphasis on antibody-Helicon conjugates (AHCs). Helicons are…
18 May 2026
Vaccine void means current Ebola outbreak declared international emergency
The World Health Organization (WHO) has declared an outbreak of Ebola disease in Sub-Saharan Africa as a public health emergency of international concern due to the absence of any approved…
18 May 2026
Tracy Beth Høeg ousted from FDA in wider senior leadership shakeup
After just six months at the helm of the US Food and Drug Administration’s (FDA’s) drug evaluation centre, Tracy Beth Høeg has reportedly been ousted from her position – further…
18 May 2026
Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF
Boehringer Ingelheim has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Jascayd…
18 May 2026
FDA approves Enhertu for two HER2-positive early breast cancer indications
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for two new indications in human epidermal growth factor receptor 2 (HER2)-positive early breast…